Exelixis’s Cabometyx Plus Tecentriq Disappoints In Lung Cancer

Earlier Data Showed Better Results For Roche Pairing

 
• By Joseph Haas
  
Lung Cancer
Updated data put Cabometyx's utility in lung cancer in doubt
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D